All Dr Michael J. Wick (Chief Scientific Officer at The START Center for Cancer Research and Co-founder of XenoSTART) articles
-
ArticlePDX models are back – and they’re exposing what cell lines missed
As cancer drugs continue to fail in translation, researchers are turning back to patient-derived xenograft (PDX) models – this time with better science. Could they be the missing link between the lab and the clinic?